A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864 on ClinicalTrials.gov · last registry update 2026-09-03
An unusually large phase 3: 5,531 participants, more than double the 424 typical for the stage. Completed 1 June 2026. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 5,531
- Started
- 2023-11-20
- Primary completion
- 2026-06-01 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate non-inferiority)
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.